<DOC>
	<DOCNO>NCT02561156</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability pharmacokinetics ( PK ) TAK-653 administer single multiple oral dos escalate dose level healthy participant .</brief_summary>
	<brief_title>Phase 1 TAK-653 Escalating Single Multiple Dose Study Healthy Participants</brief_title>
	<detailed_description>The drug test study call TAK-653 . TAK-653 test treat people depression . This study look tolerability PK TAK-653 healthy participant . The study enroll approximately 72 participant . This study consist 2 part : Part 1- single-rising dose ( SRD ) consist 5 cohort Part 2- single multiple rise dose ( SRD/MRD ) consist 4 cohort . Participants randomly assign ( chance , like flip coin ) within cohort receive TAK-653 placebo remain undisclosed participant study doctor study ( unless urgent medical need ) . Participants enrol Cohort 1 Part 1 receive TAK-653 0.3 mg TAK-653 placebo-matching tablet Day 1 . TAK-653 dose subsequent cohort Part 1 base data previous participant . Part 2 initiated review available safety , tolerability , PK pharmacodynamics ( PD ) data collect least first 3 SRD cohort . All participant ask take drug time day Day 1 Part 1 Day 1 Days 6 18 Part 2 . This single-center trial conduct United Kingdom . The overall time participate study approximately 14 day Part 1 31 day Part 2 . Participants admit clinic 6 day Part 1 22 day Part 2 . Participants follow 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<criteria>1 . Is capable understand comply protocol requirement . 2 . Signs date write , informed consent form require privacy authorization prior initiation study procedure include request participant fast laboratory evaluation . 3 . Weighs least 45 kilogram ( kg ) body mass index ( BMI ) 18.0 30.0 kilogram per square meter ( kg/m^2 ) , inclusive Screening . 4 . Male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 90 day 5 halflives elapse since last dose study drug . This interpreted 90 day Followup Call/Visit unless data indicates otherwise . 5 . Female participant childbearing potential sexually active nonsterilized male partner agree routinely use highly effective contraception low user dependency signing informed consent , throughout duration study , 30 day 5 halflives elapse since last dose study drug . This interpreted 30 day Followup Call/Visit unless data indicates otherwise . 1 . Has receive investigational compound within 90 day prior first dose study drug . 2 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( example , spouse , parent , child , sibling ) may consent duress . 3 . Has clinically significant illness , cardiovascular , neurologic , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , immunologic , endocrine , psychiatric disease disorder , abnormality , may affect safety , increase risk seizure lower seizure threshold , potentially confound study result . It responsibility investigator assess clinical significance ; however , consultation Takeda Medical Monitor may warrant . 4 . Has know hypersensitivity component formulation TAK653 . 5 . Has take exclude medication , supplement , food product time period . 6 . Is pregnant lactate intend become pregnant , , within 30 day 5 halflives elapse since last dose study drug ( 30 day Followup Call/Visit unless available data indicates otherwise ) ; intend donate ova time period . 7 . If male , intend donate sperm course study within 90 day 5 halflives elapse since last dose study drug . This interpreted 90 day Followup Call/Visit unless data indicates otherwise . 8 . Has previous episode seizure convulsion ( lifetime ) , include absence seizure febrile convulsion . 9 . Participant immediate family member history epilepsy ( include febrile convulsion ) . 10 . Has history neurological abnormality include abnormal EEG screen brain injury include traumatic injury , perinatal cerebropathy postnatal brain damage , bloodbrain barrier abnormality , angioma cavernous . 11 . Has history cerebral arteriosclerosis . 12 . Has condition potentially reduce drug clearance ( example , renal hepatic insufficiency ) . 13 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( , history malabsorption , surgical intervention know impact absorption [ example , bariatric surgery bowel resection ] , esophageal reflux , peptic ulcer disease , erosive esophagitis , frequent [ per week ] occurrence heartburn ) . 14 . Has history cancer , except basal cell carcinoma remission least 5 year prior Checkin ( Day 1 ) . 15 . Has positive test result hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody , know history human immunodeficiency virus ( HIV ) infection Screening . 16 . Has poor peripheral venous access . 17 . Has positive urine/blood result drug abuse ( define illicit drug use ) Screening Checkin ( Day 1 ) . 18 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior Screening unwilling agree abstain alcohol drug throughout study . 19 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum ) within 28 day prior Checkin Day 1 . Cotinine test positive Screening Checkin ( Day 1 ) . 20 . Has donate lose 450 milliliter ( mL ) blood volume ( include plasmapheresis ) , transfusion blood product within 90 day prior first dose study drug . 21 . Has Screening Checkin ( Day 1 ) abnormal ( clinically significant [ CS ] ) ECG . Entry subject abnormal ( clinically significant [ NCS ] ) ECG must approve , document signature principal investigator medically qualify subinvestigator . In case QT interval correct use Fridericia 's formula ( QTcF ) interval great ( &gt; ) 450 millisecond ( msec ) &gt; 480 msec ( subject Bundle Branch Block ) PR outside range 120 220 msec , assessment may repeat eligibility determination Screening Visit and/or Checkin ( Day 1 ) Visit . 22 . Has supine blood pressure outside range &gt; =90 &lt; =140 millimeter mercury ( mmHg ) systolic great equal ( &gt; = ) 50 less equal ( &lt; = ) 90 mm Hg diastolic . If range , assessment may repeat eligibility determination Screening Visit and/or Checkin ( Day 1 ) . 23 . Has rest heart rate outside range 50 90 bpm ( ECGs ) . If range , assessment may repeat eligibility determination Screening Visit and/or Checkin ( Day 1 ) . 24 . Has abnormal Screening Checkin ( Day 1 ) laboratory value suggest clinically significant underlying disease subject follow lab abnormality : Alanine transaminase ( ALT ) and/or Aspartate aminotransferase ( AST ) &gt; 1.5 upper limit normal ( ULN ) . 25 . Has risk suicide per CSSRS ( score 4 5 ideation suicidal behavior ) accord investigator 's clinical judgment , make suicide attempt previous 6 month , history deliberate selfharm past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>